Objective-To explore whether ␣-lipoic acid (ALA), a naturally occurring antioxidant, inhibits neointimal hyperplasia by inducing apoptosis of vascular smooth muscle cells and to examine its potential effects on reendothelialization and platelet aggregation. Methods and Results-Restenosis and late stent thrombosis, caused by neointimal hyperplasia and delayed reendothelialization, are significant clinical problems of balloon angioplasty and drug-eluting stents. ALA treatment strongly induced apoptosis of vascular smooth muscle cells and enhanced the expression and cytoplasmic localization of Nur77, which triggers intrinsic apoptotic events. Small interfering RNA-mediated downregulation of Nur77 diminished this proapoptotic effect of ALA. Moreover, ALA increased p38 mitogen-activated protein kinase phosphorylation, and inhibition of p38 mitogen-activated protein kinase completely blocked ALA-induced vascular smooth muscle cell apoptosis and Nur77 induction and cytoplasmic localization. In balloon-injured rat carotid arteries, ALA enhanced Nur77 expression and increased TUNEL-positive apoptotic cells in the neointima, leading to inhibition of neointimal hyperplasia. This preventive effect of ALA was significantly reduced by infection of an adenovirus encoding Nur77 small hairpin (sh)RNA. Furthermore, ALA reduced basal apoptosis of human aortic endothelial cells and accelerated reendothelialization after balloon injury. ALA also suppressed arachidonic acid-induced platelet aggregation. Conclusion-ALA could be a promising therapeutic agent to prevent restenosis and late stent thrombosis after angioplasty and drug-eluting stent implantation. (Arterioscler Thromb Vasc Biol. 2010;30:2164-2172.)
R estenosis caused by neointimal hyperplasia is a main obstacle in the long-term success of percutaneous coronary intervention, such as balloon angioplasty and stenting. Neointimal hyperplasia is characterized by diffuse intimal thickening, resulting from uncontrolled proliferation of vascular smooth muscle cells (VSMCs). [1] [2] [3] Along with excessive proliferation of VSMCs, decreased VSMC apoptosis also plays a crucial role in the development and progression of neointimal hyperplasia. 4 -6 The intrinsic antiapoptotic phenotype, leading to diabetic vasculopathy, was observed in neointimal VSMCs isolated from patients with diabetes mellitus. 4 Inhibition of antiapoptotic B cell lymphoma-x (Bcl-x) expression induces VSMC apoptosis and reduces neointimal hyperplasia and intimal lesion formation. 5, 6 Drug-eluting stents (DESs), which locally release antiproliferative drugs, profoundly reduce the rate of in-stent restenosis. 3 However, late stent thrombosis (LST) associated with delayed reendothelialization remains a major problem, limiting the long-term efficacy and safety of DESs. 3, 7 Delayed or incomplete reendothelialization contributes to neointimal hyperplasia, and accelerated reendothelialization inhibits restenosis and LST. [7] [8] [9] Therefore, pharmacological agents that inhibit proliferation and increase apoptosis in VSMCs while accelerating reendothelialization appear to be useful for the prevention of restenosis and LST after DES implantation.
Nur77, also known as nuclear receptor subfamily 4 group A member1 (NR4A1), nerve growth factor-induced clone B, and TR3, is a transcription factor that belongs to a nuclear hormone receptor superfamily. 10 Nur77 is implicated in both cell survival and apoptosis, depending on the cell types and agents used, although its precise physiological function is not yet fully understood. Nur77 is transiently induced by serum and growth factors and exerts mitogenic effects through its direct binding to a conserved DNA element and transactivation function in the nucleus. 11, 12 It is also upregulated in response to diverse apoptotic stimuli and exhibits a proapoptotic action in T cells and cancer cell lines. [13] [14] [15] [16] This proapoptotic feature of Nur77 is associated with its translocation from nucleus to mitochondria, where it interacts with Bcl-2. 17 This interaction, in turn, induces a conformational change in Bcl-2, leading to conversion of Bcl-2 from an antiapoptotic to a proapoptotic molecule to initiate apoptosis by triggering cytochrome C release from mitochondria. Overexpression or activation of Nur77 also protects against neointimal hyperplasia through inhibition of VSMC proliferation. 18, 19 However, the physiological relevance of the proapoptotic role of Nur77 in neointimal hyperplasia has been poorly investigated.
␣-Lipoic acid (1,2-dithiolane-3-pentanoic acid [ALA]), a naturally occurring powerful antioxidant, induces apoptosis of several tumor cell lines. 20 -22 Several lines of evidence from clinical and experimental data also suggest that ALA could be used to prevent the development of atherosclerosis. 21, 23 It was previously reported that ALA improves vascular dysfunction and prevents free fatty acid-induced apoptosis of vascular endothelial cells by activating AMP-activated protein kinase. 24 It was also demonstrated that ALA prevents neointimal hyperplasia in balloon-injured (BI) rat carotid artery models through downregulation of the chemokine and adhesion molecules by inhibiting nuclear factor (NF)-B activity. 25, 26 However, the potential proapoptotic effect of ALA on VSMCs and its role in postinjury reendothelialization and platelet aggregation have not yet been explored.
In this study, we investigated whether ALA inhibits neointimal hyperplasia via induction of VSMC apoptosis and identified the signaling pathways involved in this process. Also, we examined the potential effect of ALA on postinjury reendothelialization and platelet aggregation.
Methods
Male Sprague-Dawley rats (Hyochang, Daegu, Korea), aged 7 to 8 weeks and weighing 280 to 300 g, were used in the experiments. All procedures complied with the institutional guidelines for animal research.
An expanded Methods section is available in the supplemental data (available online at http://atvb.ahajournals.org).
Results

ALA Induces Apoptosis of VSMCs
Based on our observation of a dramatic decrease in the number of VSMCs by ALA treatment (data not shown), we investigated the effect of ALA on VSMC proliferation and apoptosis through cell cycle analysis using flow cytometry. ALA treatment for 22 hours suppressed cell cycle progression from G 0 /G 1 to S phase in serum-stimulated VSMCs (supplemental Figure I) . When VSMCs were incubated in complete medium containing 10% FBS and ALA for 72 hours, the percentage of cells in the sub-G 1 phase, indicative of an apoptotic population, was greatly enriched ( Figure 1A) . In contrast, the sub-G 1 population was modestly increased in quiescent VSMCs, which were incubated in medium with 0.5% FBS and ALA (supplemental Figure II) . This result suggests that ALA induces apoptosis more potently in proliferating than quiescent VSMCs. This proapoptotic effect of ALA on VSMCs was further confirmed by TUNEL staining ( Figure 1B ).
In addition, ALA significantly increased the expression of a proapoptotic molecule, BCL2-associated X protein (Bax), and subsequent cytosolic release of cytochrome C from mitochondria ( Figure 1C ). ALA also strongly activated caspase-3, a key executioner of apoptosis, as determined by amino acid sequence Asp-Glu-Val-Asp (DEVD)ase activity ( Figure 1D ). These results demonstrate that ALA induces apoptosis of VSMCs through an intrinsic mitochondria-mediated apoptotic pathway.
ALA Enhances Expression and Cytoplasmic Localization of Nur77 in VSMCs
Nur77 is induced in response to various apoptotic stimuli and is involved in the intrinsic apoptotic pathway in cancer cell lines. [13] [14] [15] [16] [17] Thus, we examined the effect of ALA on Nur77 expression in VSMCs. Replacement with complete medium without ALA resulted in a rapid and transient induction of Nur77 mRNA that increased at 30 minutes to 2 hours but returned to baseline levels by 4 hours (Figure 2A , left). In contrast, Nur77 mRNA expression was slightly enhanced by ALA at 2 hours and significantly induced at 8 to 24 hours, suggesting biphasic induction of Nur77 by ALA. In addition, a transient transfection assay showed that ALA increased Nur77 promoter activity, suggesting that ALA regulates Nur77 expression at a transcriptional level (Figure 2A , right).
Immunocytochemical staining revealed that complete medium alone transiently increased nuclear Nur77 protein expression, whereas ALA-containing complete medium further enhanced cytoplasmic and nuclear Nur77 expression at 2 hours ( Figure 2B ). Cytoplasmic Nur77 expression persisted up to 12 hours, although the signal was weak, whereas it was rarely detected in ALA-untreated VSMCs. Moreover, similar to other apoptotic stimuli, 12 ALA repressed transcriptional activity of Nur77 (supplemental Figure III) , implying that the nuclear transactivation function of Nur77 is dispensable for the proapoptotic effect of ALA.
Immunofluorescence analysis also showed that a significant amount of Nur77 was diffusely distributed throughout the cytoplasm in ALA-treated, but not untreated, VSMCs ( Figure  2C ). ALA induced cytoplasmic localization of some fraction of Nur77 protein, noticeably in mitochondria, as evidenced by partial coimmunostaining with heat shock protein 60, a mitochondria-specific protein. 16 Moreover, Nur77 interacted with Bcl-2 in the presence of ALA ( Figure 2D ), implying that ALA-induced VSMC apoptosis can be mediated by the interaction of Nur77 with Bcl-2, similar to previous reports. 16, 17 Altogether, these findings demonstrate that ALA enhances the expression and nuclear export of Nur77, and interaction between Nur77 and Bcl-2, leading to subsequent VSMC apoptosis.
Nur77 Is Required for ALA-Induced VSMC Apoptosis
To verify the requirement of Nur77 for ALA-induced VSMC apoptosis, we examined the effect of knockdown of Nur77. ALA-induced Nur77 expression was profoundly reduced by transient transfection of small interfering RNA (siRNA) targeting Nur77 (Nur77-siRNA) but not control siRNA (Con-siRNA) ( Figure 3A ). The percentage of ALA-increased apoptotic cells was evidently reduced by Nur77-siRNA, indicating that Nur77 is indispensable for ALA-induced VSMC apoptosis ( Figure 3B and C) . Similarly, ALA-induced caspase-3 activity was significantly diminished by Nur77-siRNA ( Figure 3D ). Taken together, these results reveal that Nur77 is required for ALA-induced apoptosis of VSMCs.
p38 Mitogen-Activated Protein Kinase Plays a Critical Role in ALA-Induced VSMC Apoptosis Through Modulation of Expression and Cytoplasmic Localization of Nur77
To clarify the signal transduction pathways involved in ALA-induced Nur77 expression and apoptosis, we examined the effect of inhibitors of diverse signaling pathways, including mitogen-activated protein kinases (MAPKs) (ie, extracellular signal-regulated kinase [ERK], JNK, and p38 MAPK), protein kinase A, protein kinase C, and phosphatidylinositol 3-kinase. Among the inhibitors tested, only SB203580, a selective inhibitor of p38 MAPK, completely blocked ALAinduced Nur77 mRNA expression and morphological changes in VSMCs; although GF109203X, a protein kinase C inhibitor, also showed a modest effect ( Figure 4A ). In contrast, inhibition of ERK, JNK, protein kinase A, and phosphatidylinositol 3-kinase further enhanced Nur77 expression and could not reverse the morphological changes of VSMCs evoked by ALA.
As expected, ALA increased p38 MAPK phosphorylation from 30 minutes up to 8 hours, whereas it moderately inhibited JNK and ERK1/2 phosphorylation ( Figure 4B ). ALA-induced increases in the sub-G 1 cell population and caspase-3 activity were markedly suppressed by SB203580 but not by an ERK inhibitor, PD98059 ( Figure 4C ). Moreover, ALA-induced cytoplasmic localization of Nur77 was extensively reduced by SB203580 ( Figure 4D ). Collectively, these findings demonstrate that ALA induces apoptosis of VSMCs through p38 MAPK-dependent induction and cytoplasmic localization of Nur77.
ALA Prevents Neointimal Hyperplasia Via Induction of Nur77-Mediated VSMC Apoptosis
To validate the proapoptotic effect of ALA on VSMCs in vivo, we used a rat carotid artery BI model; and TUNEL staining was performed on the sections of arteries of rats intraperitoneally administered saline (vehicle) or ALA from 3 day before to 14 days after BI. ALA administration significantly reduced neointimal hyperplasia in the vessels at 14 days after BI ( Figure 5A and supplemental Figure IV ). There were few apoptotic cells in uninjured control arteries, irrespective of ALA treatment ( Figure 5B, left) , indicating no toxic effect of ALA on healthy arteries. In contrast, TUNELpositive cells were greatly increased in injured arteries of rats given ALA. Similar results were obtained by transmission electron microscopy (supplemental Figure V) . Moreover, apoptotic cells were detected predominantly in the neointima of ALA-treated arteries, where VSMCs actively proliferate, compared with those in the media. This result was consistent with the observation that proliferating neointimal VSMCs were more sensitive to the proapoptotic effect of ALA versus quiescent medial VSMCs ( Figure 5C ).
In agreement with TUNEL staining, strong cytoplasmic Nur77 expression was observed, especially in the neointima of ALA-treated arteries at 14 days after BI; whereas it was barely detected in either media or neointima of saline-treated arteries (Figure 5B, right) . To confirm the requirement of Nur77 for a protective effect of ALA against neointimal hyperplasia, we infused adenoviruses encoding shRNA against Nur77 or control shRNA in BI carotid arteries. Adenoviruses encoding shRNA against Nur77, but not adenoviruses encoding control shRNA, significantly reduced the inhibitory effect of ALA on neointima formation ( Figure  5D and supplemental Figure VI) . This finding demonstrates a requirement of Nur77 for ALA-induced protection against neointimal hyperplasia. Altogether, these results demonstrate that ALA prevents neointimal hyperplasia after vascular Figure 2 . ALA enhances the expression and cytoplasmic localization of Nur77. A, ALA increased Nur77 expression at a transcriptional level. At 24 hours after seeding of VSMCs, medium was replaced with fresh complete medium containing ALA. Cells were then incubated for indicated times and harvested for semiquantitative RT-PCR (left). Levels of Nur77 mRNA were normalized against those of ␤-actin, and data in the bar graph are the meanϮSE of 3 independent measurements. *PϽ0.05 and **PϽ0.01 vs control. Transient transfection assay results are also given (right). VSMCs were transfected with Nur77 pro-Luc and treated with ALA for 24 hours. Luciferase activity was normalized to ␤-galactosidase activity. *PϽ0.05 vs reporter alone. B, Immunocytochemical staining for Nur77 in VSMCs treated with ALA, 2 mmol/L. C, Subcellular localization of Nur77 was detected by immunofluorescence. VSMCs were treated with ALA for 2 hours and immunostained with anti-Nur77 and anti-heat shock protein (HSP) 60 antibodies. Cells were stained with 4Ј,6-diamidino-2-phenylindole (DAPI) to identify nuclei. Nur77, HSP60 (mitochondria), and DAPI (nuclei) were visualized by confocal microscopy; and the images were overlaid. D, ALA stimulates the interaction between Nur77 and Bcl-2. VSMCs were treated with ALA, cell lysates were immunoprecipitated using anti-Nur77 antibody, and the immune complex was subjected to Western blotting with anti-Bcl-2 antibody. Con indicates control; Nur77 pro-Luc, Nur77 promoter-driven luciferase reporter.
injury, at least partly through induction of Nur77-mediated apoptosis in VSMCs.
ALA Accelerates Reendothelialization After BI and Inhibits Platelet Aggregation
Incomplete or delayed reendothelialization, leading to LST, remains a major problem of DESs; and accelerated reendothelialization has reduced restenosis and LST. 3, [7] [8] [9] Based on previous studies 24, 27 showing protective effects of ALA on endothelial cells, we examined the effect of ALA on reendothelialization by immunohistochemical staining for CD31, an endothelial-specific marker, on the sections of arteries harvested at various points (3, 10, and 14 days after injury). ALA significantly increased CD31 reactivity on the luminal surface of arteries at 10 to 14 days after injury, whereas a CD31 signal was undetectable in injured arteries without ALA administration ( Figure 6A) .
In contrast with its proapoptotic action in VSMCs, ALA did not induce apoptosis of human aortic endothelial cells (HAECs); rather, it inhibited basal apoptosis of HAECs ( Figure 6B) whereas it inhibited proliferation of HAECs ( Figure 6C ). Moreover, ALA strongly inhibited arachidonic acid-induced platelet aggregation, suggesting its antithrombotic property ( Figure 6D ). Taken together, these results propose that ALA may prevent restenosis and LST after DES implantation through facilitation of reendothelialization and direct inhibition of platelet aggregation.
Discussion
In this study, we demonstrate that ALA inhibits neointima formation in BI rat carotid arteries by inducing apoptosis of VSMCs. We also elucidated the detailed molecular mechanisms underlying ALA-induced VSMC apoptosis, which was associated with the p38 MAPK/Nur77-mediated apoptotic pathway. In contrast, ALA inhibited basal apoptosis of endothelial cells and accelerated reendothelialization after BI. We also found an antiplatelet aggregation effect of ALA. Therefore, our findings suggest that ALA may prevent restenosis and LST after DES implantation through induction of VSMC apoptosis and acceleration of reendothelialization, along with its direct antithrombotic effect.
ALA has induced or inhibited apoptosis, depending on the cell types and cellular context. 20, 22, 24 However, the detailed mechanisms of its conflicting actions in relation to apoptosis have not been fully investigated. Previously, ALA prevented apoptosis of endothelial cells via AMP-activated protein kinase phosphorylation and antioxidative function. 24 Herein, we demonstrated differential effects on apoptosis of VSMCs and endothelial cells. We elucidated the molecular mechanism underlying proapoptotic action of ALA on VSMCs, involving p38 MAPK-dependent Nur77 induction and cytoplasmic localization. In contrary, ALA inhibited basal apoptosis of HAECs, even at a high concentration (4 mmol/L), and accelerated reendothelialization in vivo. This antiapoptot- VSMCs were transfected with siRNA, targeting Nur77 (Nur77-siRNA) or control (scrambled) siRNA (Con-siRNA) for 24 hours, serum starved for 24 hours, and then incubated in fresh complete medium containing ALA for 2 hours. B through D, VSMCs were transfected with Nur77-siRNA or Con-siRNA, incubated in complete medium containing ALA for 72 hours (B and C) or 48 hours (D), and analyzed by flow cytometry (B and C) or measurement of caspase-3 activity (D). *PϽ0.005 vs Con-siRNA without ALA, and **PϽ0.01 vs Con-siRNA with ALA (C); and *PϽ0.01 vs Con-siRNA without ALA, and **PϽ0.05 vs Con-siRNA with ALA (D).
ic action of ALA might be mediated through activation of AMP-activated protein kinase or acutely transforming retrovirus AKT8 in rodent T cell lymphoma (AKT), as suggested in previous studies. 24, 27 Further studies are necessary to elucidate the molecular mechanism of antiapoptotic action of ALA in HAECs.
Recently, Nur77 family members have emerged as potentially important factors in the complex network of proteins that modulate endothelial cell activation and VSMC proliferation in atherosclerosis. 10,28 -30 Overexpression of TR3 in the arterial VSMCs and activation of Nur77 by 6-mercaptopurine protect against neointimal formation through inhibition of PD, PD98059, an ERK1/2 inhibitor (40 mol/L); SP, SP600125, a JNK inhibitor (10 mol/L); GF, GF109203X, a protein kinase C inhibitor (1 mol/L); Wort, Wortmannin, a phosphatidylinositol 3-kinase inhibitor (500 nmol/L); and H89, a protein kinase A inhibitor (1 mol/L). B, ALA increased p38 MAPK phosphorylation. VSMCs were treated with fresh complete medium with or without ALA for indicated times, and whole cell extracts were subjected to Western blotting. C, Inhibition of p38 MAPK blocked ALA-induced VSMC apoptosis. VSMCs were pretreated with SB203580 or PD98059 for 1 hour before ALA treatment for 72 hours and analyzed by flow cytometry and measurement of caspase-3 activity. *PϽ0.01 vs control at 48 hours, and **PϽ0.01 vs ALA alone. D, Cells were treated with SB203580 for 1 hour before ALA treatment for 2 hours and fixed for immunostaining with anti-Nur77 and anti-heat shock protein (HSP) 60 antibodies. DAPI indicates 4Ј,6diamidino-2-phenylindole; p, phosphorylated.
excessive VSMC proliferation via induction of cell cycle arrest but not apoptosis. 18, 19 Herein, we suggest an alternative inhibitory mechanism of neointimal hyperplasia by ALA through induction of p38 MAPK/Nur77-mediated apoptosis of VSMCs. ALA-induced VSMC apoptosis and protection against neointimal hyperplasia were significantly abrogated by downregulation of Nur77. It was previously reported that ALA inhibited vascular inflammation by inhibiting the NF-B pathway, leading to the inhibition of neointimal hyperplasia. 24 -26 Considering the previous reports 28 -30 that Nur77 inhibits NF-B activity, it is also plausible that the anti-inflammatory effect of ALA may be mediated, at least in part, by Nur77. In support of this theory, we found that Nur77 siRNA significantly reduced the inhibitory effect of ALA on TNF-␣-stimulated NF-B activity (supplemental Figure VII) . Therefore, ALA may exert antirestenotic effects primarily through Nur77 because ALA-induced Nur77 could mediate the anti-inflammatory action of ALA in injured vessels and because of its proapoptotic effect on proliferating VSMCs. However, further studies are needed to confirm the hypothesis in vivo and to identify the transcription factors mediating ALA responsiveness on the Nur77 gene promoter.
Recent advances in DESs, such as sirolimus-or paclitaxeleluting stents, have significantly reduced the incidence of in-stent restenosis. However, the risk of LST remains a severe complication after DES implantation and is caused, in part, by delayed or incomplete reendothelialization because of its Figure 5 . ALA prevents neointimal hyperplasia via induction of Nur77mediated VSMC apoptosis. A, Representative photomicrographs of crosssections of uninjured (con) and BI carotid arteries of rats given saline or ALA, 50 and 100 mg/kg per day, from 3 days before to 14 days after BI (hematoxylin-eosin [H&E] stain, original magnification ϫ100). B, TUNEL staining (left) and immunohistochemical staining (right) for Nur77 were performed on the cross-sections (hematoxylin stain, original magnification ϫ200). C, Neointimal VSMCs are more sensitive to ALAinduced apoptosis than medial VSMCs. Neointimal and medial VSMCs were incubated with ALA, 1 and 2 mmol/L, for 72 hours and analyzed by flow cytometry. D, Adenoviruses encoding shRNA against Nur77 (Ad-shNur77) markedly diminished the inhibitory effect of ALA on neointimal hyperplasia. Ad-shNur77 or adenoviruses encoding control shRNA (Ad-shRNA) were infused into BI carotid arteries of rats immediately after injury, and rats were given ALA from 3 days before to 14 days after BI (H&E stain, original magnification ϫ100). Immunohistochemical staining for Nur77 (brown) was performed (hematoxylin stain, original magnification ϫ200).
cytotoxic effects on endothelial cells and VSMCs and vascular inflammation. 3,7-9 Therefore, successful development of a DES has relied on discovery of agents that play opposite actions in VSMCs and endothelial cells in terms of proliferation and apoptosis. In addition, antiplatelet therapy is mandatory to prevent LST after DES implantation, although there is still a debate about the optimal duration of antiplatelet therapy. 3, 7, 31 Herein, we demonstrated that ALA prevented HAEC apoptosis and accelerated postinjury reendothelialization in vivo. We also showed an antiplatelet aggregation property of ALA, suggesting its direct antithrombotic effect. Collectively, our previous and present studies suggest that Figure 6 . ALA accelerates postinjury reendothelialization and inhibits platelet aggregation. A, Immunohistochemical staining for CD31 (brown), an endothelial-specific marker, was performed on the cross-sections of control arteries and the arteries of rats administered saline or ALA, 100 mg/kg per day, and harvested at 3, 10, and 14 days after BI (hematoxylin stain, original magnification ϫ200). B, ALA inhibits basal apoptosis of HAECs. HAECs were treated with ALA for 72 hours and analyzed by flow cytometry. C, ALA inhibited proliferation of HAECs. Serum-starved HAECs with 0.5% FBS for 24 hours were stimulated with 10% FBS and ALA for 16 hours and incubated with 5-bromodeoxyuridine (BrdU) for an additional 2 hours. *PϽ0.001 vs control, and **PϽ0.01 and # PϽ0.001 vs serumstimulated activity. D, ALA inhibits arachidonic acid (AA)-induced human platelet aggregation. Human platelets were incubated with ALA and stimulated with AA, 1 mmol/L. ALA can be a promising therapeutic agent used in DESs for the prevention of restenosis and LST after DES implantation because of its pleiotropic effects on diverse vascular and inflammatory cells.
